Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

Expert Opinion on Drug Safety

Volumn 14, Issue 3, 2015, Pages 429-437

  McLaughlin, Maeve ^a   Östör'S, Andrew ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Humanized anti IL 6 receptor (IL 6R) antibody; Immunotherapy; Rheumatoid arthritis; Safety; Tocilizumab

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TOCILIZUMAB; ANTIRHEUMATIC AGENT; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

CLINICAL TRIAL (TOPIC); DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; INJECTION SITE REACTION; NEUTROPENIA; REVIEW; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA; TUBERCULOSIS; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; DRUG COMBINATION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERLEUKIN-6;

EID: 84923320624     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.998198     Document Type: Review

References (39)

1. Woolf D, Bruce P; World Health Organisation Special Theme - Bone and Joint Decade 2000 - 2010. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003.81(9):646-56. Available from: http://www.who.int/bulletin/volumes/81/ 9/Woolf.pdf
2. Abdel-Nasser AM, Rasker JJ, Valkenburg HA. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum 1997;27:123-40
3. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014;73(7):1316-22
4. McWilliams D, Varughese S, Young A, et al. Work disability and state benefit claims in early rheumatoid arthritis: the ERAN cohort. Rheumatology 2014;53(3):473-81
5. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFa inhibitors and rituximab. Ann Rheum Dis 2013; doi:10.1136/annrheumdis-2013-204021
6. Quan L, Thiele G, Tian J, et al. The development of novel therapies for rheumatoid arthritis. Expert Opin Ther Pat 2008;18(7):723-38
7. http://www.rheumatology.org/practice/ clinical/patients/diseases-and-conditions/ rheumatoid-arthritis/
8. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological diseasemodifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73(3):516-28
9. Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford) 2006;45(12):1575-6
10. Tanaka T, Kishimoto T. The Biology and Medical Implications of Interleukin-6. Cancer Immunol Res 2014;2(4):288-94
11. Ash Z, Emery P. The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin Biol Ther 2012;12(9):1277-89
12. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73(1):69-74
13. Ogota A, Tanimura K, Sugimoto T, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66(3):344-54
14. NICE technology appraisals [TA198]. Tocilizumab for the treatment of rheumatoid arthritis. 2010;Available from: https://www.nice. org.uk/Guidance/TA198
15. NICE technology appraisals [TA247]. Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198). 2012;Available from: https://www.nice. org.uk/guidance/ta247
16. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebocontrolled, randomised trial. Lancet 2008;371(9617):987-97
17. Genovese M, McKay 2, Nasonov E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58(10):2968-80
18. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebocontrolled trial. Ann Rheum Dis 2008;67(11):1516-23
19. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the ambition study. Ann Rheum Dis 2010;69(1):88-96
20. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled Phase IV trial. Lancet 2013;381(9877):1541-50
21. Mariette X, Gottenberg JE, Ravaud P, et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the french registries. Rheumatology 2011;50(1):222-9
22. Morel J, Duzanski MO, Flipo RM, et al. Prospective follow-up of tocilizumab treatment in 1503 patients with refractory rheumatoid arthritis: tolerance data at 1 year from the french registry regate (registry - roactemra). Ann Rheum Dis 2014;73(Suppl2):503
23. Leffers HC, Ostergaard M, Glintborg B, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish danbio registry. Ann Rheum Dis 2011;70:1216-22
24. Hetland ML, Lindegaard HM, Hansen A, et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? results from the nationwide danish danbio Registry. Ann Rheum Dis 2008;67:1023-6
25. Specker C, Kaufmann J, Vollmer MA, et al. Tocilizumab in rheumatoid arthritis - one year interim analysis of the noninterventional ichiban study. Ann Rheum Dis 2012;71(Suppl 3):667
26. Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab vs placebo in combination with disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66(11):1653-61
27. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. The summacta study: efficacy and safety of tocilizumab subcutaneous versus tocilizumab intravenous, in combination with traditional dmards, in patients with rheumatoid arthritis at 49 weeks. ACR 2013;464
28. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19(1):12-19
29. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6
30. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21
31. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25:40-6
32. Kaine J, Gladstein G, Strusberg I, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (Phase IIIb ALLOW study). Ann Rheum Dis 2012;71:38-44
33. Malaviya A, Ledingham J, Bloxham J, et al. The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. Rheumatology 2014;53:1344-6
34. Van Vollenhoven RF, Nishimoto N, Yamanaka H. Experience with Mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety database. Ann Rheum Dis 2009;68(Suppl 3):567
35. Genovese MC, Sebba A, Rubbert-Roth A, et al. Long-term safety of tocilizumab in rheumatoid arthritis clinical trials. In: Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professional; 5-9 November 2011; Chicago, IL
36. Roche Registration Ld. RoActemra 20 mg/ml concentrate for solution for infusion [summary of product characteristics]. Welwyn Garden City, UK: 2011. Available from: http://www.roche. fr/content/dam/corporate/roche-fr/doc/ RoActemra10139573MAJ27-06-12.pdf
37. Navarro-Millan I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 2012;34(4):788-802
38. Available from: http://www. rheumatology.org.uk/includes/documents/ cm-docs/2014/t/ts-id-5689- nice-letter-to-manufacturer-confirming- topic-not-progressing- past-decision-point-1- june-2014.pdf
39. Mocsai A, Kovacs L, Gergely P. What is the furtue of targeted therapy in rheumatology: biologics or small molecules? BMC Medicine 2014;12:43